Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
17.06. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.05. | Citizens JMP reiterates Foghorn stock with $9 target | 2 | Investing.com | ||
FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
14.05. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
14.05. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
01.05. | Foghorn Therapeutics erweitert Vorstand mit Biotech-Veteranen | 2 | Investing.com Deutsch | ||
01.05. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors | 1 | GlobeNewswire (USA) | ||
30.04. | Foghorn stock holds at $9 target, JMP affirms Market Outperform | 3 | Investing.com | ||
28.04. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update | 1 | GlobeNewswire (USA) | ||
28.04. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
23.04. | JMP starts Foghorn stock with $9 target, sees major opportunity | 1 | Investing.com | ||
15.04. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
25.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting | 72 | GlobeNewswire (Europe) | - FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical... ► Artikel lesen | |
20.03. | Foghorn Therapeutics scales down ATM stock offering to $100M | 1 | Seeking Alpha | ||
20.03. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
07.03. | H.C. Wainwright maintains $13 target on Foghorn shares | 1 | Investing.com | ||
06.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook | 107 | GlobeNewswire (Europe) | First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary... ► Artikel lesen | |
06.03. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
03.02. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
30.01. | Foghorn Therapeutics a new buy at B Riley on tumor fighting technology | 3 | Seeking Alpha | ||
24.01. | Foghorn Therapeutics files for mixed shelf offering | 5 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |